Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Quinazolinone fungal efflux pump inhibitors. Part 2: In vitro structure-activity relationships of (N-methyl-piperazinyl)-containing derivatives.

Watkins WJ, Lemoine RC, Chong L, Cho A, Renau TE, Kuo B, Wong V, Ludwikow M, Garizi N, Iqbal N, Barnard J, Jankowska R, Singh R, Madsen D, Lolans K, Lomovskaya O, Oza U, Dudley MN.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5133-7.

PMID:
15380214
2.
3.

The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogues of diamine-containing efflux pump inhibitors.

Watkins WJ, Landaverry Y, Léger R, Litman R, Renau TE, Williams N, Yen R, Zhang JZ, Chamberland S, Madsen D, Griffith D, Tembe V, Huie K, Dudley MN.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4241-4.

PMID:
14623009
4.

MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.

Nakayama K, Ishida Y, Ohtsuka M, Kawato H, Yoshida K, Yokomizo Y, Ohta T, Hoshino K, Otani T, Kurosaka Y, Yoshida K, Ishida H, Lee VJ, Renau TE, Watkins WJ.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4205-8.

PMID:
14623002
5.

MexAB-OprM-specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization.

Nakayama K, Ishida Y, Ohtsuka M, Kawato H, Yoshida Ki, Yokomizo Y, Hosono S, Ohta T, Hoshino K, Ishida H, Yoshida K, Renau TE, Léger R, Zhang JZ, Lee VJ, Watkins WJ.

Bioorg Med Chem Lett. 2003 Dec 1;13(23):4201-4.

PMID:
14623001
6.

Conformationally-restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Filonova L, Flamme EM, Wang M, Yen R, Madsen D, Griffith D, Chamberland S, Dudley MN, Lee VJ, Lomovskaya O, Watkins WJ, Ohta T, Nakayama K, Ishida Y.

Bioorg Med Chem Lett. 2003 Aug 18;13(16):2755-8.

PMID:
12873508
7.

Molecular basis for fungal selectivity of novel antimitotic compounds.

Lila T, Renau TE, Wilson L, Philips J, Natsoulis G, Cope MJ, Watkins WJ, Buysse J.

Antimicrob Agents Chemother. 2003 Jul;47(7):2273-82.

8.

Peptidomimetics of efflux pump inhibitors potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Yen R, She MW, Flamme EM, Sangalang J, Gannon CL, Chamberland S, Lomovskaya O, Lee VJ.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):763-6.

PMID:
11858997
9.

Addressing the stability of C-capped dipeptide efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa.

Renau TE, Léger R, Flamme EM, She MW, Gannon CL, Mathias KM, Lomovskaya O, Chamberland S, Lee VJ, Ohta T, Nakayama K, Ishida Y.

Bioorg Med Chem Lett. 2001 Mar 12;11(5):663-7.

PMID:
11266165
10.

Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy.

Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ.

Antimicrob Agents Chemother. 2001 Jan;45(1):105-16.

11.

Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin.

Renau TE, Léger R, Flamme EM, Sangalang J, She MW, Yen R, Gannon CL, Griffith D, Chamberland S, Lomovskaya O, Hecker SJ, Lee VJ, Ohta T, Nakayama K.

J Med Chem. 1999 Dec 2;42(24):4928-31. No abstract available.

PMID:
10585202
12.

Nonnucleoside pyrrolopyrimidines with a unique mechanism of action against human cytomegalovirus.

Jacobson JG, Renau TE, Nassiri MR, Sweier DG, Breitenbach JM, Townsend LB, Drach JC.

Antimicrob Agents Chemother. 1999 Aug;43(8):1888-94.

13.

N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies.

Klopman G, Fercu D, Renau TE, Jacobs MR.

Antimicrob Agents Chemother. 1996 Nov;40(11):2637-43.

14.

Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position.

Renau TE, Gage JW, Dever JA, Roland GE, Joannides ET, Shapiro MA, Sanchez JP, Gracheck SJ, Domagala JM, Jacobs MR, Reynolds RC.

Antimicrob Agents Chemother. 1996 Oct;40(10):2363-8.

15.
16.
17.

Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N-1 and C-7.

Renau TE, Sanchez JP, Gage JW, Dever JA, Shapiro MA, Gracheck SJ, Domagala JM.

J Med Chem. 1996 Feb 2;39(3):729-35.

PMID:
8576916
18.

Synthesis and evaluation of certain thiosangivamycin analogs as potential inhibitors of cell proliferation and human cytomegalovirus.

Krawczyk SH, Renau TE, Nassiri MR, Westerman AC, Wotring LL, Drach JC, Townsend LB.

J Med Chem. 1995 Sep 29;38(20):4115-9.

PMID:
7562947
19.

Effect of lipophilicity at N-1 on activity of fluoroquinolones against mycobacteria.

Renau TE, Sanchez JP, Shapiro MA, Dever JA, Gracheck SJ, Domagala JM.

J Med Chem. 1995 Jul 21;38(15):2974-7.

PMID:
7636859
20.

Relationship between cytotoxicity and conversion of thiosangivamycin analogs to toyocamycin analogs in cell culture medium.

Renau TE, Lee JS, Kim H, Young CG, Wotring LL, Townsend LB, Drach JC.

Biochem Pharmacol. 1994 Aug 17;48(4):801-7.

21.

Improved synthesis and biological evaluation of an acyclic thiosangivamycin active against human cytomegalovirus.

Renau TE, Nassiri MR, Swayze EE, Kern ER, Townsend LB, Drach JC.

Antiviral Res. 1992 Jul 1;19(1):15-28.

Supplemental Content

Support Center